OncoMatch/Clinical Trials/NCT05145400
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
Is NCT05145400 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Isatuximab and Lenalidomide for multiple myeloma.
Treatment: Isatuximab · Lenalidomide · Dexamethasone — This research study is investigating the safety and effectiveness of using combination of isatuximab, lenalidomide and dexamethasone for the treatment of newly diagnosed multiple myeloma (MM). The study team will use lower doses than is currently standard for these drugs. Lower doses will be used to avoid or possibly reduce any unwanted side effects commonly associated with these drugs. Using lower doses of the combination isatuximab, lenalidomide and dexamethasone, has not been approved by the Food and Drug Administration (FDA) for the treatment of newly diagnosed MM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
KARNOFSKY 0–70
Prior therapy
Cannot have received: systemic anti-myeloma therapy
Exception: ≤ 28 days (generally one cycle) allowed; any prior therapy must be completed ≥ 14 days before starting study drugs
No prior systemic anti-myeloma therapy lasting more than 28 days (generally one cycle). Any prior therapy must be completed a minimum of 14 days before starting study drugs.
Lab requirements
Blood counts
Hemoglobin (Hgb) ≥ 8 g/dL (transfusion or erythropoietin permitted); ANC ≥ 1.0 x 10^9/L (growth factors permitted if due to MM); Platelets ≥ 50 × 10^9/L if < 50% BM plasma cells, ≥ 30 × 10^9/L if ≥ 50% BM plasma cells (transfusions permitted)
Kidney function
Any GFR as long as not currently dialysis-dependent
Demonstrate adequate organ function and laboratory values as defined in below.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina
- Levine Cancer Institute · Charlotte, North Carolina
- Duke Comprehensive Cancer Center · Durham, North Carolina
- Novant Health New Hanover Regional Medical Center · Wilmington, North Carolina
- The Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify